Infection Control Unit, Avicenne University Hospital, Assistance Publique - Hôpitaux de Paris, Bobigny.
INSERM, Infection Antimicrobial Modelling Evolution, UMR 1137, Paris Diderot, Sorbonne Paris Cité University, France.
Clin Infect Dis. 2019 May 30;68(12):2125-2130. doi: 10.1093/cid/ciy864.
The rising burden of intensive care unit (ICU)-acquired infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) strengthens the requirement for efficient prevention strategies. The detection of intestinal carriage of ESBL-E through active surveillance cultures (ASC) and the implementation of contact precautions (CP) in carriers are currently advocated in most high-income countries, to prevent cross-transmission and subsequent ESBL-E infections in critically-ill patients. Yet, recent studies have challenged the benefit of ASC and CP in controlling the spread of ESBL-E in ICUs with high compliance to standard hygiene precautions and no ongoing outbreak of ESBL-producing Klebsiella pneumoniae or Enterobacter spp. Besides, given their debated performance to positively predict which patients are at risk of ESBL-E infections, ASC results appear of limited value to rationalize the empirical use of carbapenems in the ICU, emphasizing the urgent need for novel anticipatory and diagnostic approaches. This Viewpoint article summarizes the available evidence on these issues.
由于产超广谱β-内酰胺酶的肠杆菌科(ESBL-E)的存在,重症监护病房(ICU)获得性感染的负担不断增加,这就需要有效的预防策略。目前,大多数高收入国家都提倡通过主动监测培养(ASC)来检测肠道携带 ESBL-E,并对携带者实施接触预防(CP),以防止 ICU 中危重症患者的交叉传播和随后的 ESBL-E 感染。然而,最近的研究对 ASC 和 CP 在控制 ICU 中 ESBL-E 传播的有效性提出了质疑,因为这些 ICU 对标准卫生预防措施的依从性很高,且没有正在发生的产 ESBL 肺炎克雷伯菌或肠杆菌属的爆发。此外,鉴于 ASC 对积极预测哪些患者有 ESBL-E 感染风险的表现存在争议,ASC 的结果对于合理使用 ICU 中的碳青霉烯类药物的经验性治疗的价值有限,这凸显了迫切需要新的预测和诊断方法。本文观点总结了这些问题的现有证据。